Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Extending treatment eligibility for chronic hepatitis B virus infection

Nature Reviews Gastroenterology & Hepatology volume 18, pages 146–147 (2021)Cite this article

Subjects

Progress towards hepatitis B virus (HBV) elimination targets remains slow, despite efforts to support enhanced prevention, diagnosis and treatment. On the basis of insights from interventions against HIV, we argue for the wider use of antiviral therapy for HBV, highlighting the potential public health benefits in preventing liver disease and reducing transmission.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Cooke, G. S. et al. Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol. Hepatol. 4, 135–184 (2019).

    Article  Google Scholar 

  2. Marchio, A. et al. Early-onset liver cancer in South America associates with low hepatitis B virus DNA burden. Sci. Rep. 8, 12031 (2018).

    Article  Google Scholar 

  3. Zhang, W. et al. Effective viral suppression is necessary to reduce hepatocellular carcinoma development in cirrhotic patients with chronic hepatitis B: Results of a 10-year follow up. Medicine 96, e8454 (2017).

    Article  Google Scholar 

  4. Ling, S. C. & Mogul, D. Treatment of infants with hepatitis B virus: A window of opportunity? J. Hepatol. 71, 856–858 (2019).

    Article  Google Scholar 

  5. Aberra, H. et al. The WHO guidelines for chronic hepatitis B fail to detect half of the patients in need of treatment in Ethiopia. J. Hepatol. 70, 1065–1071 (2019).

    Article  Google Scholar 

  6. McNaughton, A. L. et al. Hepatitis B virus seroepidemiology data for Africa: Modelling intervention strategies based on a systematic review and meta-analysis. PLoS Med. 17, e1003068 (2020).

    Article  Google Scholar 

  7. Candotti, D. et al. Multiple HBV transfusion transmissions from undetected occult infections: revising the minimal infectious dose. Gut 68, 313–321 (2019).

    Article  CAS  Google Scholar 

  8. Hayes, R. J. et al. Effect of universal testing and treatment on HIV incidence - HPTN 071 (PopART). N. Engl. J. Med. 381, 207–218 (2019).

    Article  Google Scholar 

  9. Sali, S. et al. Comparing the efficacy and safety of treating chronic hepatitis B infection during pregnancy with lamivudine, telbivudine, and tenofovir: A meta-analysis. J. Clin. Transl Hepatol. 7, 197–212 (2019).

    PubMed  PubMed Central  Google Scholar 

  10. Park, E. S. et al. Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients. J. Hepatol. 70, 1093–1102 (2019).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

P.C.M. is funded by a Wellcome Trust intermediate fellowship (grant ref 110110Z/15/Z). A.L.M. is funded by the NIHR.

Author information

Authors and Affiliations

  1. Nuffield Department of Medicine, Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, UK

    Anna L. McNaughton & Philippa C. Matthews

  2. Faculty of Medicine, Department of Metabolism, Digestion and Reproduction, Division of Digestive Diseases, Section of Hepatology and Gastroenterology, Imperial College, London, UK

    Maud Lemoine

  3. Division of Gastroenterology, Department of Medicine, Tygerberg Academic Hospital, Cape Town, South Africa

    Christo van Rensburg

  4. Department of Microbiology and Infectious Diseases, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK

    Philippa C. Matthews

Authors
  1. Anna L. McNaughton
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maud Lemoine
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christo van Rensburg
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Philippa C. Matthews
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Philippa C. Matthews.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

McNaughton, A.L., Lemoine, M., van Rensburg, C. et al. Extending treatment eligibility for chronic hepatitis B virus infection. Nat Rev Gastroenterol Hepatol 18, 146–147 (2021). https://doi.org/10.1038/s41575-020-00398-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41575-020-00398-x

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing